BACKGROUND: In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described the ability of bortezomib to selectively eliminate alloreactive T cells in a mixed leukocyte culture, preserving non-activated T cells. Due to the role of regulatory T cells in the control of graft versus host disease, in the current manuscript we have analyzed the effect of bortezomib in regulatory T cells. DESIGN AND METHODS: Conventional or regulatory CD4(+) T cells were isolated with immunomagnetic microbeads based on the expression of CD4 and CD25. The effect of bortezomib on T-cell viability was analyzed by flow cytometry using 7-amino-actinomycin D staining. To investigate the possibility of obtaining an enriched regulatory T-cell population in vitro with the use of bortezomib, CD4(+) T cells were cultured during four weeks in the presence of anti-CD3 and anti-CD28 antibodies, IL-2 and bortezomib. The phenotype of these long-term cultured cells was studied, analyzing the expression of CD25, CD127 and FOXP3 by flow cytometry, and mRNA levels were determined by RT-PCR. Their suppressive capacity was assessed in co-culture experiments, analyzing proliferation and IFN-gamma and CD40L expression of stimulated responder T cells by flow cytometry. RESULTS: We observed that naturally occurring CD4(+)CD25(+) regulatory T cells are resistant to the pro-apoptotic effect of bortezomib. Furthermore, we found that long-term culture of CD4(+) T cells in the presence of bortezomib promotes the emergence of a regulatory T-cell population that significantly inhibits proliferation, IFN-gamma production and CD40L expression among stimulated effector T cells. CONCLUSIONS: These results reinforce the proposal of using bortezomib in the prevention of graft versus host disease and, moreover, in the generation of regulatory T-cell populations, that could be used in the treatment of multiple T-cell mediated diseases.
BACKGROUND: In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described the ability of bortezomib to selectively eliminate alloreactive T cells in a mixed leukocyte culture, preserving non-activated T cells. Due to the role of regulatory T cells in the control of graft versus host disease, in the current manuscript we have analyzed the effect of bortezomib in regulatory T cells. DESIGN AND METHODS: Conventional or regulatory CD4(+) T cells were isolated with immunomagnetic microbeads based on the expression of CD4 and CD25. The effect of bortezomib on T-cell viability was analyzed by flow cytometry using 7-amino-actinomycin D staining. To investigate the possibility of obtaining an enriched regulatory T-cell population in vitro with the use of bortezomib, CD4(+) T cells were cultured during four weeks in the presence of anti-CD3 and anti-CD28 antibodies, IL-2 and bortezomib. The phenotype of these long-term cultured cells was studied, analyzing the expression of CD25, CD127 and FOXP3 by flow cytometry, and mRNA levels were determined by RT-PCR. Their suppressive capacity was assessed in co-culture experiments, analyzing proliferation and IFN-gamma and CD40L expression of stimulated responder T cells by flow cytometry. RESULTS: We observed that naturally occurring CD4(+)CD25(+) regulatory T cells are resistant to the pro-apoptotic effect of bortezomib. Furthermore, we found that long-term culture of CD4(+) T cells in the presence of bortezomib promotes the emergence of a regulatory T-cell population that significantly inhibits proliferation, IFN-gamma production and CD40L expression among stimulated effector T cells. CONCLUSIONS: These results reinforce the proposal of using bortezomib in the prevention of graft versus host disease and, moreover, in the generation of regulatory T-cell populations, that could be used in the treatment of multiple T-cell mediated diseases.
Authors: Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek Journal: Blood Date: 2005-11-08 Impact factor: 22.113
Authors: Belén Blanco; José A Pérez-Simón; Luis I Sánchez-Abarca; Xonia Carvajal-Vergara; Juan Mateos; Belén Vidriales; Natalia López-Holgado; Patricia Maiso; Mercedes Alberca; Eva Villarón; David Schenkein; Atanasio Pandiella; Jesús San Miguel Journal: Blood Date: 2005-11-10 Impact factor: 22.113
Authors: Teresa Caballero-Velázquez; Luis Ignacio Sánchez-Abarca; Silvia Gutierrez-Cosio; Belén Blanco; Cristina Calderon; Carmen Herrero; Soraya Carrancio; Concepción Serrano; Consuelo del Cañizo; Jesús F San Miguel; José A Pérez-Simón Journal: Haematologica Date: 2012-04-24 Impact factor: 9.941
Authors: Alex F Herrera; Haesook T Kim; Bhavjot Bindra; Kyle T Jones; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Sarah Nikiforow; Bruce R Blazar; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth Journal: Biol Blood Marrow Transplant Date: 2014-07-10 Impact factor: 5.742
Authors: T Caballero-Velázquez; C Calderón-Cabrera; L López-Corral; N Puig; F Marquez-Malaver; E Pérez-López; C García-Calderón; C M Rosso-Fernández; D Caballero Barrigón; J Martín; M V Mateos; J San Miguel; J A Pérez-Simón Journal: Bone Marrow Transplant Date: 2019-09-24 Impact factor: 5.483